These direct HIF2α inhibitors are efficacious in rodent cancer models, and, importantly, demonstrate antitumour activity in metastatic clear-cell renal cell carcinoma (ccRCC) patients along with a favourable safety and tolerability profile [21–25]. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.